Generation and Characterization of a Diabody Targeting the αvβ6 Integrin

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Kogelberg, Heide ^a   Miranda, Enrique ^a   Burnet, Jerome ^b   Ellison, David ^b   Tolner, Berend ^a   Foster, Julie ^b   Picón, Carmen ^a   Thomas, Gareth J ^c   Meyer, Tim ^a   Marshall, John F ^b   Mather, Stephen J ^b   Chester, Kerry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; B6.3 DIABODY; B6.3 DIABODY TC 99M; BISPECIFIC ANTIBODY; HEXAHISTIDINE; RECOMBINANT ANTIBODY; SHMFE23 DIABODY; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PICHIA PASTORIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTEGRINS; ISOTOPE LABELING; MICE; PICHIA; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TECHNETIUM;

EID: 84883332077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073260     Document Type: Article

References (38)

1. Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, et al. (2010) The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 52: 362-369.
2. Bandyopadhyay A, Raghavan S, (2009) Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 10: 645-652.
3. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, et al. (2004) Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45: 226-236.
4. Bates RC, (2005) Colorectal cancer progression: integrin alphavbeta6 and the epithelial-mesenchymal transition (EMT). Cell Cycle 4: 1350-1352.
5. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, et al. (2007) Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 212: 316-324.
6. Thomas GJ, Nystrom ML, Marshall JF, (2006) Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 35: 1-10.
7. Shi M, Zhu J, Wang R, Chen X, Mi L, et al. (2011) Latent TGF-beta structure and activation. Nature 474: 343-349.
8. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM, (2001) AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 92: 641-650.
9. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, et al. (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328.
10. Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, et al. (2008) Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol) 20: 61-66.
11. Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, et al. (2008) Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci 99: 879-887.
12. Mamuya FA, Duncan MK, (2012) aV integrins and TGF-beta-induced EMT: a circle of regulation. J Cell Mol Med 16: 445-455.
13. Bates RC, Mercurio AM, (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4: 365-370.
14. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
15. Yang SB, Du Y, Wu BY, Xu SP, Wen JB, et al. (2012) Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer. Cancer Immunol Immunother 61: 335-342.
16. Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, et al. (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 68: 561-570.
17. Kogelberg H, Tolner B, Thomas GJ, Di Cara D, Minogue S, et al. (2008) Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. J Mol Biol 382: 385-401.
18. Holliger P, Prospero T, Winter G, (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90: 6444-6448.
19. Wu AM, Yazaki PJ, (2000) Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 44: 268-283.
20. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, et al. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77: 1405-1412.
21. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
22. Li L, Turatti F, Crow D, Bading JR, Anderson AL, et al. (2010) Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. J Nucl Med 51: 1139-1146.
23. DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, et al. (2007) Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem 282: 9657-9665.
24. Tolner B, Smith L, Begent RH, Chester KA, (2006) Expanded-bed adsorption immobilized-metal affinity chromatography. Nat Protoc 1: 1213-1222.
25. Tolner B, Smith L, Begent RH, Chester KA, (2006) Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc 1: 1006-1021.
26. Graff CP, Chester K, Begent R, Wittrup KD, (2004) Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel. 17: 293-304.
27. Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, et al. (2004) Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 279: 17875-17887.
28. He J, Wang Y, Feng J, Zhu X, Lan X, et al. (2010) Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med 51: 427-432.
29. Giacomini MM, Travis MA, Kudo M, Sheppard D, (2012) Epithelial cells utilize cortical actin/myosin to activate latent TGF-beta through integrin alpha(v)beta(6)-dependent physical force. Exp Cell Res 318: 716-722.
30. Sheppard D, (2003) Functions of pulmonary epithelial integrins: from development to disease. Physiol Rev 83: 673-686.
31. Roberts AB, Wakefield LM, (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100: 8621-8623.
32. Meulmeester E, Ten Dijke P, (2011) The dynamic roles of TGF-beta in cancer. J Pathol 223: 205-218.
33. Elliott RL, Blobe GC, (2005) Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093.
34. Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, et al. (2012) TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res 72: 4840-4845.
35. Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, et al. (2012) A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene.
36. Lee MS, Kim TY, Kim YB, Lee SY, Ko SG, et al. (2005) The signaling network of transforming growth factor beta1, protein kinase Cdelta, and integrin underlies the spreading and invasiveness of gastric carcinoma cells. Mol Cell Biol 25: 6921-6936.
37. Wu AM, Olafsen T, (2008) Antibodies for molecular imaging of cancer. Cancer J 14: 191-197.
38. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, et al. (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44: 1962-1969.